Study reveals the advantages and pitfalls of adding a TKI to a monoclonal antibody after chemoradiation for non-small cell ...

The FDA has granted Fast Track designation to nadunolimab to treat patients with previously untreated metastatic pancreatic ductal adenocarcinoma.

Thymic Stromal Lymphopoietin (TSLP) is a cytokine that is a key driver of the inflammatory response in major allergic and ...

DelveInsight's "Systemic Lupus Erythematosus Pipeline Insight, 2025" report delivers comprehensive insights about 120+ companies and 140+ pipeline drugs currently in the various s ...

SteinCares will handle all regulatory filings, registrations and commercialization of Ranibizumab in Latin America, while ...

Fast Track Designation (FTD) granted for the treatment of patients with metastatic PDAC with high IL1RAP expression levels.Reflects high unmet medical need in metastatic PDAC.Facilitates further devel ...

Fast Track Designation (FTD) granted for the treatment of patients with metastatic PDAC with high IL1RAP expression levels.Reflects high unmet medical need in metastatic PDAC.Facilitates further ...

MEDSIR announces positive results from TUXEDO-3 trial of patritumab deruxtecan in patients with active brain metastases and leptomeningeal disease: Chicago Monday, June 9, 2025, 1 ...

Verekitug is a novel recombinant fully human immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that binds to the TSLP receptor and inhibits proinflammatory signaling initiated by TSLP.

The agent is an investigational antibody-drug conjugate targeting HER3 and consists of a fully human anti-HER3 IgG1 monoclonal antibody attached to a topoisomerase I inhibitor payload through ...

With its existing entitlement, plus the newly acquired economics from BioInvent, XOMA Royalty will be entitled to milestones of up to USD $16.25 million from Takeda and mid-single digit royalties on ...